Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

PURPOSE: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). PATIENTS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Antoinette R., Wright, Gail S., Thummala, Anu R., Danso, Michael A., Popovic, Lazar, Pluard, Timothy J., Han, Hyo S., Vojnović, Željko, Vasev, Nikola, Ma, Ling, Richards, Donald A., Wilks, Sharon T., Milenković, Dušan, Xiao, Jie, Sorrentino, Jessica, Horton, Janet, O'Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377748/
https://www.ncbi.nlm.nih.gov/pubmed/34887261
http://dx.doi.org/10.1158/1078-0432.CCR-21-2272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377748/
https://www.ncbi.nlm.nih.gov/pubmed/34887261
http://dx.doi.org/10.1158/1078-0432.CCR-21-2272

Ejemplares similares